Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Regulatory Affairs

Breckenridge Pharmaceutical Issues Major Recall for Duloxetine Capsules

Sreepriya Prasannan
Sreepriya Prasannan

NewsWritten by our team from the primary sources linked below. Reviewed, verified and approved by a human editor. How we check

Speed:
Breckenridge Pharmaceutical Issues Major Recall for Duloxetine Capsules

Breckenridge Pharmaceutical has issued a significant voluntary recall affecting over 375,000 bottles of Duloxetine Delayed-Release Capsules, an SNRI medication commonly prescribed for depression, anxiety, and neuropathic pain. The recall, initiated in June 2026, marks the latest in a series of market withdrawals by the company over the past two years relating to the same safety concern.

A photorealistic close-up of a prescription medication bottle with green and white capsules on a pharmacy counter.
Patients are advised to check their medication lot numbers against the FDA's official recall list.

The Cause: Nitrosamine Impurities

The core issue driving the recall is the detection of N-nitroso-duloxetine, a nitrosamine impurity found in the affected batches at levels that exceed the strict daily intake limits recommended by the U.S. Food and Drug Administration (FDA).

Nitrosamines are common compounds found in water and everyday foods, including cured and grilled meats. However, prolonged exposure to these impurities at higher-than-acceptable levels over long periods can increase the risk of cancer, leading regulatory agencies to strictly monitor their presence in pharmaceutical products.


Details of the Current Recall

The June 2026 recall specifically targets multiple lots of the medication, encompassing both the 30mg and 60mg dosages:

  • 30mg Capsules: Identified under NDC 51991-747-10.
  • 60mg Capsules: Identified under NDC 51991-748-90 and NDC 51991-748-10.

The expiration dates on the affected bottles range from November 2026 through May 2027.

This is not an isolated incident for Breckenridge Pharmaceutical. The company navigated a series of similar, large-scale recalls throughout 2024 and 2025 as the pharmaceutical industry at large continues to grapple with the complex challenge of nitrosamine contamination in drug manufacturing processes.


Critical Patient Guidance

For patients currently taking duloxetine, the FDA and healthcare professionals emphasize one critical directive: Do not stop taking your medication abruptly.

Duloxetine is known to cause severe withdrawal symptoms-often referred to as discontinuation syndrome-if stopped suddenly. Symptoms can include dizziness, nausea, headache, paresthesia (brain zaps), and intense mood fluctuations.

If you are taking Breckenridge-manufactured duloxetine, you should take the following steps:

  1. Check your bottle: Look for the manufacturer name (Breckenridge Pharmaceutical) and the lot number on your prescription label.
  2. Contact your pharmacist: If the lot number matches the recalled batches, your pharmacist can verify the recall and provide a safe replacement from an unaffected batch or a different manufacturer.
  3. Consult your doctor: Discuss any concerns about your treatment plan or potential alternatives with your prescribing physician.

Maintaining patient safety while avoiding the risks of sudden drug discontinuation remains the highest priority for healthcare providers managing this ongoing recall.

Pharmaceutical Quality Control and Batch Recalls

Breckenridge Pharmaceutical's voluntary recall of several lots of Duloxetine Delayed-Release Capsules highlights the critical role of product stability testing in quality assurance. The recall was initiated after routine stability testing detected the presence of an impurity (N-nitroso-duloxetine) above the acceptable daily intake limit set by regulatory authorities. Nitrosamines are classified as probable human carcinogens, and their presence in common medications has triggered numerous recalls in recent years.

This recall requires pharmacies, distributors, and patients to immediately check their stock and return affected lots. For manufacturers, it emphasizes the importance of verifying raw material purity and validating chemical synthesis routes to prevent the formation of nitrosamine impurities during production and storage.

Frequently Asked Questions

What medication was recalled by Breckenridge Pharmaceutical?

Breckenridge recalled specific lots of Duloxetine Delayed-Release Capsules, a medication commonly prescribed to treat major depressive disorder and generalized anxiety disorder.

Why was the Duloxetine recall initiated?

The recall was triggered because testing identified levels of a nitrosamine impurity (N-nitroso-duloxetine) that exceeded the acceptable daily limit set by the FDA.

What should patients do if they have the recalled medication?

Patients should check the lot numbers on their prescription bottles. If they match the recalled lots, they should contact their pharmacy or physician for a replacement, and should not stop taking their medication without consulting their doctor.

Frequently Asked Questions

What are nitrosamines and why are they dangerous?

Nitrosamines are chemical compounds that are classified as probable human carcinogens. Long-term exposure to levels above acceptable limits may increase the risk of cancer.

Are all batches of Breckenridge Duloxetine affected?

No. The recall is limited to specific lot numbers and expiration dates identified in the manufacturer's official recall announcement.

What is the therapeutic class of Duloxetine?

Duloxetine is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) used to treat depression, generalized anxiety disorder, and diabetic peripheral neuropathy.

Frequently Asked Questions

What are nitrosamines and why are they dangerous?

Nitrosamines are chemical compounds that are classified as probable human carcinogens. Long-term exposure to levels above acceptable limits may increase the risk of cancer.

Are all batches of Breckenridge Duloxetine affected?

No. The recall is limited to specific lot numbers and expiration dates identified in the manufacturer's official recall announcement.

What is the therapeutic class of Duloxetine?

Duloxetine is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) used to treat depression, generalized anxiety disorder, and diabetic peripheral neuropathy.

Reviewed for editorial accuracy by Sreepriya Prasannan, Founder & Editor MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany
Our standards
Related from our data
Cymbalta 60 mg hard gastro-resistant capsules — Duloxetine · Irish Medicines Database Duloxetine Accord 30 mg hard gastro-resistant capsules — Duloxetine hydrochloride · Irish Medicines Database
Chemokeyp: A Feasibility Study for Realtime Safety Data-Capture for Potential Serious Adverse Drug Events — Recruiting in Ireland · Trials Tracker
Drugs in this article: current clinical trials
Most-trialled drugs in our registers
Browse all trial registers →

Get the Friday brief

One email every Friday: a 60-second summary, then only the topics you choose: industry news, approvals and market access, shortages, Irish trials, careers or data, all built from public registers.

Free. Unsubscribe from any email with one click. See our privacy policy.

About the Author
Sreepriya Prasannan

Sreepriya Prasannan

Writer at Priya Life Science · Regulatory Affairs

Sreepriya Prasannan is the Founder and Editor of Priya Life Science, Ireland's independent pharma, biotech and MedTech platform. She holds an MSc in Digital Transformation (Life Science) from Griffith College Dublin, with a background in QA, GMP and production operations. Shortlisted for STEM Graduate of the Year at the Business Post Women in STEM Awards 2026 and a Top 14 finalist in the HSE Spark Ignite 2026 innovation programme, she writes on regulatory trends, GMP compliance and careers across the Irish and European life sciences.

Discussion
No comments yet. Be the first to share your thoughts!
Leave a Comment